Table 1.
Baseline characteristics.
| Derivation, n (%) | Validation, n (%) | p value | |
|---|---|---|---|
| Number of patients | 69 | 70 | |
| Mean age in years, mean ± SD | 62.3 ± 10.7 | 63.7 ± 7.2 | 0.37 |
| Number of biopsy samples | 69 | 70 | 0.87 |
| Obtained after the last line of treatment (ACT) | 36 (52.2) | 35 (50.0) | |
| Obtained before the last line of treatment (BCT) | 33 (47.8) | 35 (50.0) | |
| Sex | 0.61 | ||
| Male | 40 (58.0) | 37 (52.9) | |
| Female | 29 (42.0) | 33 (47.1) | |
| Histological subtypes | 0.31 | ||
| Squamous | 20 (29.0) | 21 (68.6) | |
| Nonsquamous | 46 (66.7) | 48 (30.0) | |
| Other (adenosquamous, LCNEC, NOS or unknown) | 3 (4.3) | 1 (1.4) | |
| ECOG performance score | 0.59 | ||
| 0 | 7 (10.1) | 8 (11.4) | |
| 1 | 44 (63.8) | 40 (57.1) | |
| ≥2 | 16 (23.2) | 22 (31.4) | |
| Unknown | 2 (2.9) | 0 (0) | |
| DCB rate | 0.34 | ||
| Patients without DCB | 15 (21.7) | 21 (30.0) | |
| Patients with DCB | 54 (78.3) | 50 (70.0) |